Sanofi (SNY) Return on Capital Employed (2018 - 2026)
Sanofi (SNY) posted Return on Capital Employed of 76.66% for Q2 2026, up 9.27% sequentially from 70.16% in Q4 2025, and up 1699.0% YoY from 4.26% in Q2 2025.
Sanofi (SNY) Return on Capital Employed (2018 - 2026) Analysis & Trends
Sanofi has reported Return on Capital Employed for 3 years, with the latest figure at 76.66% in Q2 2026.
- Quarterly Return on Capital Employed rose 1699.0% year-over-year to 76.66% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 76.66% (up 1699.0% YoY) and the FY2025 annual result came in at 6.61%, down 56.0% from the prior year.
- Return on Capital Employed grew to 76.66% in Q2 2026 per SNY's latest filing, from 70.16% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 76.66% in Q2 2026 and troughed at 59.67% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.66% |
| Dec 31, 2025 | 70.16% |
| Jun 30, 2025 | 59.67% |
| Dec 31, 2018 | 157.95% |
| Sep 30, 2018 | 103.76% |
| Mar 31, 2018 | 66.63% |